People: Immunomedics Inc (IMMU.W)
IMMU.W on CBOE When Trading NASDAQ Global Select Market
4.46USD
19 Jun 2013
4.46USD
19 Jun 2013
Price Change (% chg)
$0.16 (+3.72%)
$0.16 (+3.72%)
Prev Close
$4.30
$4.30
Open
$4.41
$4.41
Day's High
$4.50
$4.50
Day's Low
$4.36
$4.36
Volume
4,000
4,000
Avg. Vol
1,779
1,779
52-wk High
$4.50
$4.50
52-wk Low
$2.26
$2.26
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
David Goldenberg |
74 | 2007 | Chairman of the Board, Chief Scientific Officer, Chief Medical Officer |
Cynthia Sullivan |
57 | 2001 | President, Chief Executive Officer, Director |
Gerard Gorman |
61 | 2006 | Chief Financial Officer, Senior Vice President - Finance |
Morton Coleman |
73 | 2000 | Director |
Marcella LoCastro |
61 | 2012 | Director |
Brian Markison |
53 | 2010 | Independent Lead Outside Director |
Mary Paetzold |
62 | 2001 | Independent Director |
Donald Stark |
58 | 2005 | Independent Director |
Biographies
| Name | Description |
|---|---|
David Goldenberg |
Dr. David M. Goldenberg is Chairman of the Board, Chief Scientific Officer, Chief Medical Officer of Immunomedics, Inc. He founded Immunomedics in July 1982, and has served continuously since that time as the Chairman of the company's Board of Directors. He also currently serves as the company's Chief Scientific Officer and Chief Medical Officer, having been Chief Strategic Officer from July 2003 to July 2007. Dr. Goldenberg previously served as the company's Chief Executive Officer from July 1982 through July 1992, from February 1994 through May 1998 and from July 1999 through March 2001. He also serves as Chairman of the Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics. Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg (Germany) School of Medicine (M.D.). Dr. Goldenberg is President and a Trustee of the Center for Molecular Medicine and Immunology (“CMMI”), an independent non-profit research center, and its clinical unit, the Garden State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an “Outstanding Investigator Grant” award from the National Cancer Institute for his work in radioimmunodetection, and in 1986 he received the New Jersey Pride Award in Science and Technology. Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology and in 2002, the Elis Bervin Lectureship and Medal from the Swedish Medical Society and the Swedish Oncology Society for his contributions to the development of radiolabeled monoclonal antibodies used. |
Cynthia Sullivan |
Ms. Cynthia L. Sullivan is President, Chief Executive Officer, Director of Immunomedics, Inc. She has been employed by Immunomedics since October 1985, and has served as the company's President and Chief Executive Officer since March 2001. She previously served as the Company’s President from December 2000 to March 2001 and as Executive Vice President and Chief Operating Officer from June 1999 to December 2000. Prior to joining Immunomedics, Ms. Sullivan was employed by Ortho Diagnostic Systems, Inc., a subsidiary of Johnson & Johnson. Ms. Sullivan’s educational background includes: a B.S. from Merrimack College, North Andover, Massachusetts, followed by a year of clinical internship with the school of Medical Technology at Muhlenberg Hospital, Plainfield, New Jersey, resulting in a M.T. (ASCP) certification in 1979. Ms. Sullivan completed a M.S. degree in 1986 from Fairleigh Dickinson University, where she also received her M.B.A. in December 1991. Ms. Sullivan also serves as President of the company's majority owned subsidiary, IBC Pharmaceuticals, Inc. From September 2002 to July 2007, Ms. Sullivan served as a member of the Board of Directors of Digene Corp., a company that develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. Effective July 30, 2007 Digene Corp was merged with Qiagen N.V. From November, 2007 to December 2009, Ms. Sullivan served as a member of the Board of Directors of Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders. As of May 2009, Ms. Sullivan also serves as a member of Board of Trustees for the HealthCare Institute of New Jersey, a trade association for the research-based pharmaceutical and medical technology industry in New Jersey. |
Gerard Gorman |
Mr. Gerard G. Gorman is Chief Financial Officer, Senior Vice President - Finance of Immunomedics, Inc., since June 2006. He was Vice President, Finance and Chief Financial Officer from September 2001 until June 2006. From 1996 to 2001, Mr. Gorman was employed by the Animal Health Division of Pfizer Inc., where he was Vice President, Finance and Information Technology and Chief Financial Officer. While at Pfizer, Mr. Gorman directed strategic and long-range financial planning as well as negotiations related to acquisitions, divestitures and outsourcing of support operations. Mr. Gorman previously held a variety of other senior positions at Pfizer, including: Senior Director, Corporate Treasury Operations; Director, Administration—International Pharmaceuticals Group; Director, Finance/Assistant Treasurer International; and Manager, Benefit Financing/Senior Financial Analyst. Mr. Gorman completed a B.A. in economics from Fairfield University and received his M.B.A. from Adelphi University. Mr. Gorman also serves as a member of the Board of Directors of the Northern Ireland Children’s Enterprise and as a member of the Board of Trustees of the Mianus River Gorge Preserve. |
Morton Coleman |
Dr. Morton Coleman is Director of Immunomedics, Inc. He is Clinical Professor of Medicine.He is Director of the Center for Lymphoma and Myeloma in the Division of Hematology Oncology since 1997, at New York Presbyterian Hospital—Cornell Medical Center, Clinical Professor of Medicine at the Weill Medical College of Cornell University since 1986 and Published investigator and opinion leader in hematological malignancies. |
Marcella LoCastro |
Ms. Marcella LoCastro, CPA, CITP, serves as Director of Immunomedics, Inc., since March 6, 2012. Ms. LoCastro is the Chief Executive Officer of MLoCastro Consulting LLC, and provides Women's Leadership Training for public accounting and professional services firms, as well as the New Jersey Society of Certified Public Accountants. Previously, she served as a Managing Partner at Tatum, LLC, a national professional services firm, Managing Director at SolomonEdwardsGroup, LLC, a national CFO services firm, and has held Partner roles with Deloitte LLP, JH Cohn LLP, Arthur Andersen LLP and Ernst & Young LLP. Ms. LoCastro currently serves on the Board and the Audit Committee of BioClinica, Inc. (Nasdaq:BIOC); as a Senior Advisor on an Industry Advisory Board for Alvarez and Marsal; and as a board member of several professional and educational organizations. |
Brian Markison |
Mr. Brian A. Markison is an Independent Lead Outside Director of Immunomedics, Inc. He is President, Chief Executive Officer and Chairman of Board of Directors, King Pharmaceuticals, Inc., since May 2004. Previously he served as President of Bristol-Myers Squibb’s Oncology, Virology and Oncology Therapeutics Network Businesses from 2002 until 2004. From 1999 to 2001, Mr. Markison served in various positions, including President, Bristol-Myers Squibb’s Oncology, Virology and Oncology Therapeutics Network Dupont Integration; Senior Vice President, Licensing and External Development. He is Chairman of the Board of Directors of King Pharmaceuticals, Inc., a vertically integrated pharmaceutical company engaged in the development, manufacturing, marketing and sales of branded prescription pharmaceutical products, since December 2006. |
Mary Paetzold |
Ms. Mary E. Paetzold is an Independent Director of Immunomedics, Inc. She is Retired Certified Public Accountant with over 35 years of experience with public and private companies, retired since 2003. She was Adjunct Professor, Cameron School of Business, University of North Carolina – Wilmington from 2008 to 2009, Vice President, Chief Financial Officer, Secretary, and Treasurer of Ecogen, Inc., from 1994 to 2000, member of the Ecogen Board of Directors from 1996 to 1997 and Served as audit partner, and as SEC reviewing partner, at KPMG LLP, an independent registered public accounting firm, prior to 1994. |
Donald Stark |
Mr. Donald C. Stark is an Independent Director of Immunomedics, Inc. He is Chief Executive Officer and President of Whistler Associates, Inc., a marketing and strategic planning consulting firm for companies focused on oncology, since 1996. From 1980 to 1995, Mr. Stark served in various market research, marketing and business development positions at Bristol-Myers Squibb Oncology Division, Immunex and Repligen, all in the fields of oncology and immunology. From 2002 to the present, he has concurrently served as partner and member of the Board of Directors of Strategic Answers, Inc., a strategic planning consulting firm. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
David Goldenberg |
1,944,940 |
Cynthia Sullivan |
1,301,310 |
Gerard Gorman |
417,842 |
Morton Coleman |
-- |
Marcella LoCastro |
-- |
Brian Markison |
-- |
Mary Paetzold |
-- |
Donald Stark |
-- |
As Of 29 Jun 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
David Goldenberg |
1,800,000 | 645,000 |
Cynthia Sullivan |
1,310,000 | 186,000 |
Gerard Gorman |
400,000 | 45,250 |
Morton Coleman |
0 | 0 |
Marcella LoCastro |
0 | 0 |
Brian Markison |
0 | 0 |
Mary Paetzold |
0 | 0 |
Donald Stark |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
STARK DON C |
3,000 | $0.00 |
COLEMAN MORTON |
5,050 | $3.00 |
COLEMAN MORTON |
200 | $3.03 |
COLEMAN MORTON |
5,000 | $3.00 |
MARKISON BRIAN A |
5,000 | $0.00 |
COLEMAN MORTON |
5,000 | $0.00 |
PAETZOLD MARY E |
5,000 | $0.00 |
STARK DON C |
5,000 | $0.00 |
COLEMAN MORTON |
3,324 | $3.08 |
COLEMAN MORTON |
176 | $3.07 |
COLEMAN MORTON |
500 | $3.09 |
COLEMAN MORTON |
1,000 | $3.09 |
COLEMAN MORTON |
3,367 | $3.13 |
COLEMAN MORTON |
1,133 | $3.14 |
COLEMAN MORTON |
500 | $3.15 |
COLEMAN MORTON |
1,248 | $3.16 |
COLEMAN MORTON |
2,216 | $3.14 |
COLEMAN MORTON |
600 | $3.15 |
COLEMAN MORTON |
836 | $3.17 |
COLEMAN MORTON |
100 | $3.18 |
COLEMAN MORTON |
5,000 | $3.05 |
COLEMAN MORTON |
900 | $3.06 |
COLEMAN MORTON |
1,623 | $3.05 |
COLEMAN MORTON |
2,377 | $3.04 |
COLEMAN MORTON |
100 | $3.07 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
